PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Tan, A.T.* ; Schreiber, S.

Adoptive T-cell therapy for HBV-associated HCC and HBV infection.

Antiviral Res. 176:104748 (2020)
DOI PMC
Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.
Chronic hepatitis B virus (HBV) infection remains a major global concern due to its high prevalence and the increased probability of progressing toward cirrhosis and hepatocellular carcinoma (HCC). While currently available therapies are effective in controlling HBV replication, they rarely achieve functional cure. Similarly, effective treatment options for HBV-related HCC (HBV-HCC) are limited and primarily applicable only for early stages of the disease. With the general success of chimeric antigen receptor T-cell immunotherapy against B-cell leukemia, adoptively transferring engineered autologous T cells specific for HBV or HCC antigens might represent a promising therapeutic approach for both chronic HBV infection and HBV-HCC. This review will describe the novel T cell-related immunotherapies being developed for both indications and discuss the approach of each strategy, their considerations and limitations when applied for treatment of chronic HBV infection (CHB) and HBV-HCC.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
4.101
0.996
3
3
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Review
Schlagwörter Hepatitis-b-virus; Chimeric Antigen Receptor; Enhanced Antitumor-activity; Hepatocellular-carcinoma; Alpha-fetoprotein; Surface-proteins; Viral Clearance; Immune-response; Pre-s; Cd8(+)
Sprache englisch
Veröffentlichungsjahr 2020
HGF-Berichtsjahr 2020
ISSN (print) / ISBN 0166-3542
e-ISSN 1872-9096
Zeitschrift Antiviral Research
Quellenangaben Band: 176, Heft: , Seiten: , Artikelnummer: 104748 Supplement: ,
Verlag Elsevier
Verlagsort Amsterdam
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Virology (VIRO)
POF Topic(s) 30203 - Molecular Targets and Therapies
Forschungsfeld(er) Immune Response and Infection
PSP-Element(e) G-502700-003
DOI 10.1016/j.antiviral.2020.104748
WOS ID WOS:000523597500017
Scopus ID 85079891306
PubMed ID 32087191
Erfassungsdatum 2020-03-11
[➜Korrektur melden]